News

Members of the U.K.-based European Vasculitis Society (EUVAS) have accepted recently published recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). However, EUVAS clinicians don’t necessarily agree with the recommendations’ suggestion to use Rituxan (rituximab) to treat patients who have eosinophilic granulomatosis with polyangiitis (EGPA). The study, “Validation…

Methotrexate is an effective and safe option for remission maintenance therapy in patients with anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV), a study has found. The study, “Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: A randomised trial,” was published in the journal Plos One. AAV…

Long-term maintenance therapy with azathioprine (AZA) does not improve relapse rates in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), according to researchers. The study, “Long term azathioprine maintenance therapy in ANCA-associated vasculitis: combined results of long-term follow-up data,” was published in the journal…

More therapies are now available for the 30 million or so people with rare diseases in the U.S. than ever before, and millions of dollars are being invested in clinical studies that will test new ways of evaluating — and advancing — potential treatments, including the use of natural history…

As Congress begins debate this week to overhaul the U.S. tax code, lawmakers should leave the Orphan Drug Act (ODA) — and the tax incentives it offers pharmaceutical companies to develop therapies for rare diseases — off the table. That’s the message being pushed by the National Organization for…

About a fifth of ANCA-associated vasculitis patients have an eye disorder known as inflammatory ocular disease, a Mayo Clinic study shows. The research, published in the journal Rheumatology, was titled “Clinical characteristics of inflammatory ocular disease in anti-neutrophil cytoplasmic antibody associated vasculitis: a retrospective cohort study.” ANCA-associated vasculitis, or AAV, affects…

Although certain immune cells are present at lower levels in patients with anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV), it is due to non-specific renal injury rather than the disease itself, study shows. The study, “Alterations in circulating lymphoid cell populations in systemic small vessel vasculitis are non-specific…

Different types of ANCA-associated vasculitis occur in different ethnic groups, a study reports. The research, “Global ethnic and geographic differences in the clinical presentations of anti-neutrophil cytoplasm antibody􏰀associated vasculitis,” was published in the journal Rheumatology. Anti-neutrophil cytoplasm antibodies-associated vasculitis, or AAV, refers to three…

The protein TIMP1 is a promising biomarker of ANCA-associated vasculitis activity, according to a Japanese study that also identified markers of the disease’s damage to the kidneys and lungs. Altogether, the researchers identified nine proteins that could be suitable biomarkers. Researchers published their work in the journal Arthritis Research…

Lower levels of key immune system regulators in the kidneys of  ANCA vasculitis patients may indicate more severe renal injury, according to a new study from China. The study, “Complement regulatory proteins in kidneys of patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis,” appeared in the journal…